Metropolitan Life Insurance Co. NY bought a new stake in shares of Kadmon Holdings Inc (NYSE:KDMN) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 26,251 shares of the companyâ€™s stock, valued at approximately $105,000.
A number of other institutional investors have also recently bought and sold shares of the business. Vivo Capital LLC raised its holdings in shares of Kadmon by 213.6% in the 2nd quarter. Vivo Capital LLC now owns 10,454,545 shares of the companyâ€™s stock worth $68,919,000 after purchasing an additional 7,121,212 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Kadmon by 209.3% in the 2nd quarter. BlackRock Inc. now owns 4,763,436 shares of the companyâ€™s stock worth $19,005,000 after purchasing an additional 3,223,211 shares in the last quarter. Acuta Capital Partners LLC raised its holdings in shares of Kadmon by 52.3% in the 2nd quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the companyâ€™s stock worth $36,149,000 after purchasing an additional 3,110,014 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Kadmon by 490.1% in the 1st quarter. Millennium Management LLC now owns 1,847,444 shares of the companyâ€™s stock worth $7,852,000 after purchasing an additional 1,534,371 shares in the last quarter. Finally, VHCP Management II LLC bought a new stake in shares of Kadmon in the 2nd quarter worth approximately $5,632,000. 69.66% of the stock is owned by hedge funds and other institutional investors.
KDMN has been the topic of a number of research reports. HC Wainwright set a $25.00 target price on shares of Kadmon and gave the stock a â€śbuyâ€ť rating in a report on Monday, August 13th. Zacks Investment Research upgraded shares of Kadmon from a â€śholdâ€ť rating to a â€śbuyâ€ť rating and set a $4.25 price target on the stock in a report on Wednesday, July 11th. Finally, WBB Securities upgraded shares of Kadmon from a â€śsellâ€ť rating to a â€śholdâ€ť rating and set a $2.90 price target on the stock in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of â€śBuyâ€ť and an average price target of $11.43.Kadmon stock opened at $2.87 on Thursday. The company has a market capitalization of $377.76 million, a price-to-earnings ratio of -2.04 and a beta of 3.65. Kadmon Holdings Inc has a twelve month low of $2.62 and a twelve month high of $5.86.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, August 9th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reutersâ€™ consensus estimate of ($0.26) by $0.50. The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.90 million. Equities research analysts expect that Kadmon Holdings Inc will post -0.94 earnings per share for the current year.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Kadmon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kadmon and related companies with MarketBeat.com’s FREE daily email newsletter.